LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX
· Real-Time Price · USD
1.52
0.00 (0.00%)
At close: Aug 20, 2025, 9:56 AM
Revenue by Geography
| Period Ending | Dec 31, 2024 |
|---|---|
| Netherlands Revenue | 11.98M |
| Netherlands Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.55M | 3.43M | 4.48M | 2.79M | 3.02M | 2.94M | 2.28M | 2.86M | 3.7M | 3.89M | 3.58M | 3.13M | 3.17M | 4.24M | 3.77M | 3.76M | 2.76M | 1.73M | 256.61K | 773.92K | 755.14K | 751.6K | 303.87K | 315.38K | 311.95K |
| Selling, General, and Administrative Revenue Growth | -25.70% | -23.39% | +60.86% | -7.93% | +3.07% | +28.67% | -20.19% | -22.69% | -4.96% | +8.69% | +14.16% | -1.20% | -25.11% | +12.45% | +0.21% | +36.03% | +60.05% | +573.00% | -66.84% | +2.49% | +0.47% | +147.34% | -3.65% | +1.10% | n/a |
| Research and Development Revenue | 4.74M | 4.16M | 7.61M | 8.5M | 6.34M | 6.01M | 3.36M | 7.91M | 12.6M | 9.94M | 10.54M | 13.7M | 8.37M | 7.5M | 6.63M | 6.7M | 4.89M | 18.71M | 4.32M | 3.86M | 3.45M | 3.23M | 2.04M | 2.12M | 2.1M |
| Research and Development Revenue Growth | +14.03% | -45.35% | -10.53% | +34.15% | +5.44% | +78.84% | -57.53% | -37.20% | +26.71% | -5.66% | -23.05% | +63.62% | +11.66% | +13.01% | -1.03% | +36.94% | -73.84% | +332.91% | +11.97% | +11.75% | +6.80% | +58.31% | -3.65% | +1.10% | n/a |